Literature DB >> 2463906

Identification of a family of insulin-like growth factor II secreted by cultured rat epithelial-like cell line 18,54-SF: application of a monoclonal antibody.

H Tanaka1, O Asami, T Hayano, I Sasaki, Y Yoshitake, K Nishikawa.   

Abstract

Somatomedin/insulin-like growth factor (IGF)-like polypeptides (designated SMP) were purified from the serum-free conditioned medium of cultured rat epithelial-like cells, 18,54-SF. A monoclonal antibody (MAb) was produced against partially purified SMP. The antibody was immunoglobulin G1 relatively specific for multiplication-stimulating activity III-2 (rat IGF-II), with a Kd value of 5.6 X 10(-9) M. The antibody showed 100% cross-reactivity with human IGF-II and 10% cross-reactivity with human IGF-I, but did not cross-react with insulin. For purification of SMP, therefore, immunoaffinity chromatography on Sepharose coupled with the MAb was used besides a procedure including ion exchange chromatography, gel filtration, and reverse phase HPLC. The purified SMP (at least five polypeptides) each gave a single peak on reverse phase HPLC and appeared as a single band with an apparent mol wt of 5000-8000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The major components of SMP (designated HP1-SMP and HP3-SMP), which were purified about 100-fold from conditioned medium, stimulated DNA synthesis in human fibroblasts in culture and sulfation in chick embryonic cartilage in culture. These polypeptides showed almost the same cross-reactivity as multiplication-stimulating activity III-2 on RIA with the MAb. The partial amino acid sequences of HP1- and HP3-SMP were determined, and these polypeptides were identified with rat IGF-II.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2463906     DOI: 10.1210/endo-124-2-870

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma.

Authors:  H Kiaris; A V Schally; J L Varga; K Groot; P Armatis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II.

Authors:  E T Shapiro; G I Bell; K S Polonsky; A H Rubenstein; M C Kew; H S Tager
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

3.  Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.

Authors:  W H Daughaday; B Trivedi; R C Baxter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

4.  Expression of insulin-like growth factors and their receptors in human meningiomas.

Authors:  T Lichtor; M A Kurpakus; M E Gurney
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

5.  Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors.

Authors:  W H Daughaday; M Kapadia
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

6.  Immunocytochemical demonstration of IGF-II-like immunoreactivity in human paraganglioma of the craniocervical region.

Authors:  T Suzuki; M Iwafuchi; H Takahashi; F Ikuta; K Nishikawa; H Tanaka; N Yanaihara
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

7.  Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors.

Authors:  N Lamharzi; A V Schally; M Koppán; K Groot
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

8.  Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.

Authors:  A Jungwirth; A V Schally; J Pinski; G Halmos; K Groot; P Armatis; M Vadillo-Buenfil
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.